Mandate

Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA

August 13, 2020

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with its acquisition of a controlling interest of 62.7% of the French company Genkyotex SA, a leader in NOX inhibition therapies and listed on Euronext Paris and Euronext Brussels.

Calliditas is seeking to acquire all outstanding Genkyotex shares and will following completion of the control transaction, which is expected to close in October 2020, launch a mandatory cash tender offer on the same terms for the remaining shares.

Vinge’s team comprises Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Julia Hirschberg.





Vinge’s experts provide an insight into Swedish maritime law in the latest edition of International Comparative Legal Guide – Shipping Law 2022

Vinge’s experts in martime and transport law have again contributed to the Swedish chapter on maritime law in the International Comparative Legal Guides (ICLG).
August 10, 2022

Sanctions update 22 July

Further to our previous sanctions updates of 25 February, 3 March, 11 March, 16 March , 14 April and June 8, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
July 26, 2022

A new EU instrument for international procurement (IPI)

On 17 June 2022, the Council adopted a regulation on a new instrument for international procurement (“IPI”), following the formal adoption of the IPI at the European Parliament plenary session on 9 June 2022. The general objective of the IPI is to create reciprocity in the access to international public procurement markets by enabling the Commission to undertake investigations and adopt measures to open and improve access to third-country public procurement and concession markets.
July 11, 2022